Market Cap 626.00M
Revenue (ttm) 701.20M
Net Income (ttm) -72.90M
EPS (ttm) N/A
PE Ratio 14.48
Forward PE 12.60
Profit Margin -10.40%
Debt to Equity Ratio 0.13
Volume 495,800
Avg Vol 613,748
Day's Range N/A - N/A
Shares Out 46.51M
Stochastic %K 47%
Beta 1.07
Analysts Hold
Price Target $14.00

Company Profile

Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready co...

Industry: Medical Devices
Sector: Healthcare
Phone: 844 428 2667
Website: avanos.com
Address:
5405 Windward Parkway, Suite 100 South, Alpharetta, United States
ZacksResearch
ZacksResearch Feb. 25 at 6:44 PM
$AVNS beats fourth-quarter 2025 earnings estimates, but why the 10% drop? 🤔 Despite a 20.8% EPS beat and 0.7% revenue growth, shares fell nearly 10% yesterday. Year-to-date, the stock has plummeted 37.9%, significantly underperforming the industry and S&P 500. Find out what challenges lie ahead for Avanos 👉 https://www.zacks.com/stock/news/2875402/avanos-medical-stock-dips-despite-q4-earnings-beat-revenues-up-yy?cid=sm-stocktwits-2-2875402-body-35195&ADID=SYND_STOCKTWITS_TWEET_2_2875402_BODY_35195
0 · Reply
ZacksResearch
ZacksResearch Feb. 25 at 5:44 PM
$AVNS beats… and still plunges 10% ⚠️ Q4 earnings and revenue topped expectations, but margin pressure and tariff concerns clearly spooked investors, sending shares sharply lower. A classic case of good numbers overshadowed by forward risks. Is this selloff overdone or a real warning? Get the full breakdown 👉 https://www.zacks.com/stock/news/2875402/avanos-medical-stock-dips-despite-q4-earnings-beat-revenues-up-yy?cid=sm-stocktwits-2-2875402-teaser-35192&ADID=SYND_STOCKTWITS_TWEET_2_2875402_TEASER_35192
0 · Reply
JohnTill
JohnTill Feb. 24 at 3:09 PM
$AVNS Got to love that feeling when you side step missed earnings after selling out completely at posted. I will revisit in the low 12 and still a good story, especially if the tariff issue can disappear once and for all.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 24 at 12:10 PM
$AVNS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.03 up 99.65% YoY • Reported revenue of $180.9M up 0.72% YoY • Avanos Medical expects 2026 net sales to be between $700M and $720M. Adjusted diluted earnings per share are anticipated to be between $0.90 and $1.10 for the year.
0 · Reply
JohnTill
JohnTill Feb. 10 at 7:21 PM
$AVNS Nobody is following this one but since I posted my buys I will note that I decided to close this out at 14.80 today. I had a 10 base cost after a few earlier sales so tagged my 50% profit target and good enough for now. It is not the stock but the market and playing it careful. Plus that is a little too much strength, although might be front running tariff news. I will revist on signficant weakness or regret once tariffs get overturned.
1 · Reply
BalanceSheetBeacon
BalanceSheetBeacon Feb. 4 at 3:53 PM
$AVNS is a medical device company (Avanos Medical) focused on pain management and digestive health; it is executing a turnaround amidst competitive markets.
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 7:01 PM
Hold onto $AVNS — the bull case is still alive 📈 AVNS is showing solid 3Q25 momentum, driven by SNS and PMR growth, with M&A and cost cuts supporting results even as tariffs and FX volatility linger. See why AVNS still earns a spot in your portfolio 👉 https://www.zacks.com/stock/news/2825619/reasons-to-retain-avanos-medical-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825619-teaser-31086&ADID=SYND_STOCKTWITS_TWEET_2_2825619_TEASER_31086
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 6:01 PM
$AVNS up 10.1% in 6 months compared to the industry's 5.2% growth — what's driving the growth? 🚀 📈 Specialty Nutrition Systems & Pain Management segments show strong double-digit growth 🤝 Strategic M&A and portfolio optimization are expected to boost revenue and EPS ⚙️ Cost optimization initiatives targeting $15-$20M in annual savings by 2026 Discover the growth factors and challenges here 👉 https://www.zacks.com/stock/news/2825619/reasons-to-retain-avanos-medical-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825619-body-31087&ADID=SYND_STOCKTWITS_TWEET_2_2825619_BODY_31087
0 · Reply
JohnTill
JohnTill Jan. 21 at 3:16 PM
$AVNS Still rocking and 6 month high. Chart looks like a breakout but do not want to leave 30% profits on the table so just locked in a few more and now riding a "free" position. The tariff news is such a binary event I would rather not have my neck too far out.
0 · Reply
JohnTill
JohnTill Jan. 14 at 8:55 PM
$AVNS Well that worked out quick. Locked in a few above 11.90 just in case the tariff news take a while and gets my base cost down to 10. My only big concern is on the last conference call they mentioned a big China write-off coming so keeping my position down going into earnings but want that tariff pop.
0 · Reply
Latest News on AVNS
Avanos Medical, Inc. (AVNS) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 12:27 PM EST - 23 days ago

Avanos Medical, Inc. (AVNS) Q4 2025 Earnings Call Transcript


Avanos Medical, Inc. (AVNS) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:41 PM EST - 4 months ago

Avanos Medical, Inc. (AVNS) Q3 2025 Earnings Call Transcript


Avanos Medical, Inc. Announces Third Quarter 2025 Results

Nov 5, 2025, 7:00 AM EST - 4 months ago

Avanos Medical, Inc. Announces Third Quarter 2025 Results


The Bottom Fishing Club - Avanos Medical: Bargain Defensive Choice

Aug 29, 2025, 10:00 AM EDT - 7 months ago

The Bottom Fishing Club - Avanos Medical: Bargain Defensive Choice


Avanos Medical, Inc. (AVNS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 1:26 PM EDT - 8 months ago

Avanos Medical, Inc. (AVNS) Q2 2025 Earnings Call Transcript


Avanos Medical, Inc. Announces Second Quarter 2025 Results

Aug 5, 2025, 6:30 AM EDT - 8 months ago

Avanos Medical, Inc. Announces Second Quarter 2025 Results


Avanos Medical, Inc. (AVNS) Q1 2025 Earnings Call Transcript

May 6, 2025, 2:38 PM EDT - 11 months ago

Avanos Medical, Inc. (AVNS) Q1 2025 Earnings Call Transcript


Avanos Medical, Inc. Announces First Quarter 2025 Results

May 6, 2025, 7:00 AM EDT - 11 months ago

Avanos Medical, Inc. Announces First Quarter 2025 Results


Avanos Medical Inc. (AVNS) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 12:41 PM EST - 1 year ago

Avanos Medical Inc. (AVNS) Q4 2024 Earnings Call Transcript


Avanos Medical Launches New CORGRIP® SR

Nov 5, 2024, 7:00 AM EST - 1 year ago

Avanos Medical Launches New CORGRIP® SR


Avanos Medical Inc. (AVNS) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 3:28 PM EDT - 1 year ago

Avanos Medical Inc. (AVNS) Q3 2024 Earnings Call Transcript


Avanos Medical, Inc. (AVNS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 1:35 PM EDT - 1 year ago

Avanos Medical, Inc. (AVNS) Q2 2024 Earnings Call Transcript


Avanos Medical, Inc. Announces Second Quarter 2024 Results

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Avanos Medical, Inc. Announces Second Quarter 2024 Results


Avanos Medical, Inc. (AVNS) Q1 2024 Earnings Call Transcript

May 5, 2024, 8:37 AM EDT - 2 years ago

Avanos Medical, Inc. (AVNS) Q1 2024 Earnings Call Transcript


Avanos Medical, Inc. Announces First Quarter 2024 Results

May 2, 2024, 7:00 AM EDT - 2 years ago

Avanos Medical, Inc. Announces First Quarter 2024 Results


ZacksResearch
ZacksResearch Feb. 25 at 6:44 PM
$AVNS beats fourth-quarter 2025 earnings estimates, but why the 10% drop? 🤔 Despite a 20.8% EPS beat and 0.7% revenue growth, shares fell nearly 10% yesterday. Year-to-date, the stock has plummeted 37.9%, significantly underperforming the industry and S&P 500. Find out what challenges lie ahead for Avanos 👉 https://www.zacks.com/stock/news/2875402/avanos-medical-stock-dips-despite-q4-earnings-beat-revenues-up-yy?cid=sm-stocktwits-2-2875402-body-35195&ADID=SYND_STOCKTWITS_TWEET_2_2875402_BODY_35195
0 · Reply
ZacksResearch
ZacksResearch Feb. 25 at 5:44 PM
$AVNS beats… and still plunges 10% ⚠️ Q4 earnings and revenue topped expectations, but margin pressure and tariff concerns clearly spooked investors, sending shares sharply lower. A classic case of good numbers overshadowed by forward risks. Is this selloff overdone or a real warning? Get the full breakdown 👉 https://www.zacks.com/stock/news/2875402/avanos-medical-stock-dips-despite-q4-earnings-beat-revenues-up-yy?cid=sm-stocktwits-2-2875402-teaser-35192&ADID=SYND_STOCKTWITS_TWEET_2_2875402_TEASER_35192
0 · Reply
JohnTill
JohnTill Feb. 24 at 3:09 PM
$AVNS Got to love that feeling when you side step missed earnings after selling out completely at posted. I will revisit in the low 12 and still a good story, especially if the tariff issue can disappear once and for all.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 24 at 12:10 PM
$AVNS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.03 up 99.65% YoY • Reported revenue of $180.9M up 0.72% YoY • Avanos Medical expects 2026 net sales to be between $700M and $720M. Adjusted diluted earnings per share are anticipated to be between $0.90 and $1.10 for the year.
0 · Reply
JohnTill
JohnTill Feb. 10 at 7:21 PM
$AVNS Nobody is following this one but since I posted my buys I will note that I decided to close this out at 14.80 today. I had a 10 base cost after a few earlier sales so tagged my 50% profit target and good enough for now. It is not the stock but the market and playing it careful. Plus that is a little too much strength, although might be front running tariff news. I will revist on signficant weakness or regret once tariffs get overturned.
1 · Reply
BalanceSheetBeacon
BalanceSheetBeacon Feb. 4 at 3:53 PM
$AVNS is a medical device company (Avanos Medical) focused on pain management and digestive health; it is executing a turnaround amidst competitive markets.
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 7:01 PM
Hold onto $AVNS — the bull case is still alive 📈 AVNS is showing solid 3Q25 momentum, driven by SNS and PMR growth, with M&A and cost cuts supporting results even as tariffs and FX volatility linger. See why AVNS still earns a spot in your portfolio 👉 https://www.zacks.com/stock/news/2825619/reasons-to-retain-avanos-medical-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825619-teaser-31086&ADID=SYND_STOCKTWITS_TWEET_2_2825619_TEASER_31086
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 6:01 PM
$AVNS up 10.1% in 6 months compared to the industry's 5.2% growth — what's driving the growth? 🚀 📈 Specialty Nutrition Systems & Pain Management segments show strong double-digit growth 🤝 Strategic M&A and portfolio optimization are expected to boost revenue and EPS ⚙️ Cost optimization initiatives targeting $15-$20M in annual savings by 2026 Discover the growth factors and challenges here 👉 https://www.zacks.com/stock/news/2825619/reasons-to-retain-avanos-medical-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825619-body-31087&ADID=SYND_STOCKTWITS_TWEET_2_2825619_BODY_31087
0 · Reply
JohnTill
JohnTill Jan. 21 at 3:16 PM
$AVNS Still rocking and 6 month high. Chart looks like a breakout but do not want to leave 30% profits on the table so just locked in a few more and now riding a "free" position. The tariff news is such a binary event I would rather not have my neck too far out.
0 · Reply
JohnTill
JohnTill Jan. 14 at 8:55 PM
$AVNS Well that worked out quick. Locked in a few above 11.90 just in case the tariff news take a while and gets my base cost down to 10. My only big concern is on the last conference call they mentioned a big China write-off coming so keeping my position down going into earnings but want that tariff pop.
0 · Reply
JohnTill
JohnTill Jan. 13 at 6:32 PM
$AVNS Added a bunch more today at 11.58 on the almost touch of the 50MA to bring the avg. to 11.10 on a very decent position. If tariffs are reversed this adds $4+ overnight and if they are not reversed the current plan appears solid for a steady upturn in 2026-27 - win/win. Chart looks like it wants to go lower so waiting to add in the short term but that longer term chart sure looks like a wedge waiting to break to the upside with measured move $3-4 higher. Does the market already know something? HELE is the other that will add huge from here is tariffs are overturned.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 6:13 PM
$AVNS RSI: 52.56, MACD: 0.1001 Vol: 0.33, MA20: 11.61, MA50: 11.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 9 at 10:45 PM
$AVNS Share Price: $11.39 Contract Selected: Jul 17, 2026 $12.5 Calls Buy Zone: $0.96 – $1.18 Target Zone: $1.65 – $2.02 Potential Upside: 63% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Estimize
Estimize Nov. 26 at 11:00 AM
Wall St is expecting 0.25 EPS for $AVNS Q4 [Reporting 02/24 BMO] http://www.estimize.com/intro/avns?chart=historical&metric_name=eps&utm_co
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 10 at 7:54 PM
$AVNS Share Price: $11.36 Contract Selected: Apr 17, 2026 $10 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.28 – $0.34 Potential Upside: 55% ROI Time to Expiration: 157 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
d_risk
d_risk Nov. 5 at 9:41 PM
$AVNS - Avanos Medical Inc. Common Stock - 10Q - Updated Risk Factors AVNS flags new risks from recent US tariffs, possible USMCA/WTO withdrawal, and global retaliation impacting supply chains, plus warns that cuts to third-party healthcare reimbursements could materially hurt business. #MedicalDevices #GlobalTradeUncertainty #TradeTariffs #SupplyChainRisk #HealthcareReimbursement 🟢 Added 🟠 Removed https://d-risk.ai/AVNS/10-Q/2025-11-05
0 · Reply
mwb1
mwb1 Oct. 31 at 3:20 PM
0 · Reply
ZacksResearch
ZacksResearch Sep. 18 at 12:59 PM
$AVNS making moves in critical care with a new acquisition! Avanos just acquired Nexus Medical, adding cutting-edge TKO anti-reflux technology to its portfolio. This deal is expected to be immediately accretive to revenues and earnings, potentially boosting the stock in the near term. See what this means for AVNS’s growth trajectory 👉 https://www.zacks.com/stock/news/2753225/avanos-medical-buys-nexus-medical-to-bolster-critical-care-portfolio?cid=sm-stocktwits-2-2753225-body-12975&ADID=SYND_STOCKTWITS_TWEET_2_2753225_BODY_12975
0 · Reply
ZacksResearch
ZacksResearch Sep. 18 at 11:59 AM
$AVNS making moves — this acquisition could be a game-changer. By adding Nexus Medical and its TKO connector, the company instantly expands its critical care portfolio while driving immediate revenue and earnings growth. Full breakdown of the deal here 👉 https://www.zacks.com/stock/news/2753225/avanos-medical-buys-nexus-medical-to-bolster-critical-care-portfolio?cid=sm-stocktwits-2-2753225-teaser-12974&ADID=SYND_STOCKTWITS_TWEET_2_2753225_TEASER_12974
0 · Reply
ZacksResearch
ZacksResearch Sep. 10 at 5:13 PM
$AVNS dropped 22.4% YTD — what's happening? 🩺 Despite strong Q2 product performance and strategic transformation efforts, tariff risks and FX volatility are pressing hard on margins. ⚠️ Understand the risks before investing in AVNS 👉 https://www.zacks.com/stock/news/2749660/reasons-to-retain-avanos-medical-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2749660-body-11833&ADID=SYND_STOCKTWITS_TWEET_2_2749660_BODY_11833
0 · Reply
ZacksResearch
ZacksResearch Sep. 10 at 4:13 PM
$AVNS showing why it deserves a spot in portfolios right now. Solid Q2 results, strong product demand, and ongoing strategic transformation are fueling growth even with tariff and FX headwinds. See the full case for holding AVNS 👉 https://www.zacks.com/stock/news/2749660/reasons-to-retain-avanos-medical-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2749660-teaser-11830&ADID=SYND_STOCKTWITS_TWEET_2_2749660_TEASER_11830
0 · Reply